Pyriscence LLC is a revolutionary antimicrobial catheter that aims to reduce catheter-associated UTIs, one of healthcare’s largest and most expensive problems.
“This whole process has been a wild ride. Every time we meet with someone new, the word ‘excited’ gets thrown out. It keeps us pushing forward to know that someday our technology may someday save a patient’s life.”
More than 30% of hospital-acquired infections are related to catheter use. Pyriscence LLC aims to change that with a revolutionary antimicrobial catheter that aims to reduce catheter-associated UTIs, one of healthcare’s largest and most expensive problems. Pyriscence founders discovered this problem as first-year medical students, but it wasn’t until the team began working in the hospital and saw firsthand how these infections negatively impact patients’ lives that they decided to tackle it. Through research and collaboration with faculty across the university, the Pyriscence team has developed a novel catheter, which produces reactive oxygen capable of destroying bacteria, one of the same weapons used by white blood cells in the body to battle invading organisms.